NewsRelease

Cleanascite™Cited To Help Determine the Role of Lipids in SupportingImmunosuppressive Neutrophil Differentiation within Tumors

MONMOUTHJUNCTION, NJ, November4, 2024 -- Biotech Support Group reports on an article, describingthe simplicity and efficiency of their lipid clearance samplepreparation from cultured primary human neutrophils isolated from theblood of healthy donors with cancer supernatants from various humancancer cell lines. Thecitation is:

Dahal,Ankit, et al. "Platelet-activatingfactor (PAF) promotes immunosuppressive neutrophil differentiationwithin tumors." Proceedingsof the National Academy of Sciences 121.35(2024): e2406748121.

Chronicinflammatory milieu in the tumor microenvironment (TME) leads to therecruitment and differentiation of myeloid- derived suppressor cells(MDSCs). Polymorphonuclear (PMN)- MDSCs, which are phenotypically andmorphologically defined as a subset of neutrophils, cause majorimmune suppression in the TME, posing a significant challenge in thedevelopment of effective immunotherapies. Despite recent advances inour understanding of PMN- MDSC functions, the mechanism that givesrise to immunosuppressive neutrophils within the TME remains elusive.Consistent in both in vivo and in vitro systems, newly recruitedneutrophils into the tumor sites remained activated and highly motilefor several days and developed immunosuppressive phenotypes, asindicated by increased arginase 1 (Arg1) and dcTrail- R1 expressionand suppressed anticancer CD8 T cell cytotoxicity. The strongsuppressive function was successfully recapitulated by incubatingnaive neutrophils with cancer cell culture supernatant in vitro. Totest the hypothesis that cancer-secreted mediators were lipids, weselectively depleted lipids from the cancer cell supernatant using alipid-binding micelle kit (Cleanascite™). The article states “Todeplete lipids from cancer supernatant, we added Cleanascite reagent(Biotech Support Group) according to the manufacturer’s protocol.Briefly, 1:4 ratio of Cleanascite reagent was added to culture mediaat room temperature and placed on a rocking platform. After 10 min,the media was centrifuged at 1000×g for 5 min.”




Importantly,depletion of lipids did not change neutrophil activation ( Fig. 4G )but drastically abrogated the ability of neutrophils to both survivein cancer supernatant and limited the ability of neutrophils toexpress the MDSC markers, including Arg1 and dcTrail-R1 across bothmurine and human cancers ( Fig. 4 H and I ). Importantly, theprocess of lipid depletion did not alter neutrophil survival oractivation, suggesting that abrogation of MDSC phenotype is directlythe result of depleted cancer secreted lipids. Cancer metabolitesecretome analyses of the culture supernatant revealed that bothmurine and human cancers released lipid mediators to induce thedifferentiation of immunosuppressive neutrophils. The studyidentifies platelet-activation factor (PAF) as a lipid-drivenmechanism of MDSC differentiation in the tumor microenvironment,providing a potential target for cancer immunotherapy.

“Wenow have over thirty references, showing Cleanascite™ use inhelping to identify a characteristic feature of invitrocell response. Notably, this is the sixth reference that specificallyinvestigated the role of lipids in phenotype differentiation ofinnate immune cells in cancer. Unlike alternative lipid-depletionmethods that use solvents, Cleanascite™ is an aqueous suspensionproduct and so it is very compatible with cellular models of disease.The essential requirement is the maintenance of cellular activityafter lipid depletion, to determine whether lipid factors areassociated with phenotypic changes in cultured cells” states SwapanRoy, Ph.D., President and Founder of Biotech Support Group.

Downloadwhitepaper entitled “Cleanascite™- Lipid Removal and Cell Response Applications”,visit:

Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords:Lipiddepletion, lipid metabolism, Cleanascite™, Tumormicroenvironment, Myeloid-derived suppressor cells (MDSC),immunosuppressive neutrophil phenotype

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. Forthis market, key products include: AlbuVoid™ and AlbuSorb™ PLUSforalbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for targeted proteomics and family specificproteome enrichment.For more information, go tohttp://www.biotechsupportgroup.com.

ForBusiness Development,contact:MatthewKuruc 732-274-2866, [email protected]